News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
595,524 Results
Type
Article (35782)
Company Profile (113)
Press Release (559629)
Section
Business (170989)
Career Advice (2697)
Deals (32235)
Drug Delivery (64)
Drug Development (71868)
Employer Resources (155)
FDA (15321)
Job Trends (14427)
News (297095)
Policy (28723)
Tag
Academia (2637)
Africa (748)
Alabama (33)
Allergies (39)
Alliances (42571)
Alzheimer's disease (1124)
Antibody-drug conjugate (ADC) (33)
Approvals (15268)
Arizona (84)
Artificial intelligence (39)
Asia (34869)
Australia (6195)
Bankruptcy (278)
Best Places to Work (11619)
Biosimilars (49)
C2C Services and Suppliers (62337)
California (836)
Canada (639)
Cancer (153)
Career advice (2233)
CAR-T (33)
Cell therapy (65)
China (39)
Clinical research (55794)
Collaboration (47)
Colorado (34)
COVID-19 (2327)
Cystic fibrosis (71)
Diabetes (30)
Diagnostics (6122)
Diversity, equity & inclusion (38)
Drug pricing (43)
Earnings (64277)
Employer resources (131)
Europe (80330)
Events (96497)
Executive appointments (27)
FDA (15363)
Florida (106)
Funding (28)
Gene therapy (48)
GLP-1 (383)
Government (3901)
Healthcare (19516)
Hotbed/Location (409529)
Idaho (56)
Illinois (188)
Indiana (109)
Infectious disease (2338)
Inflammatory bowel disease (88)
Interviews (534)
IPO (15767)
Job creations (2854)
Job search strategy (1877)
Kansas (88)
Layoffs (330)
Legal (6272)
Liver cancer (43)
Lung cancer (31)
Maine (52)
Management (52)
Manufacturing (35)
Maryland (242)
Massachusetts (458)
Medical device (13550)
Medtech (13553)
Mergers & acquisitions (16244)
Metabolic disorders (107)
Neuroscience (1195)
New Jersey (61)
New York (82)
NextGen Class of 2024 (6671)
Non-profit (4784)
North Carolina (175)
Obesity (62)
Opinion (176)
Parkinson's disease (30)
Patents (30)
Peanut (35)
Pennsylvania (55)
People (49778)
Phase I (17279)
Phase II (24783)
Phase III (18569)
Policy (32)
Postmarket research (1999)
Preclinical (7081)
Rare diseases (91)
Real estate (4856)
Recruiting (61)
Regulatory (19226)
Research institute (2418)
Resumes & cover letters (442)
South America (1070)
Startups (3011)
Texas (90)
United States (2986)
Vaccines (359)
Washington State (117)
Weight loss (51)
Date
Today (73)
Last 7 days (495)
Last 30 days (1908)
Last 365 days (39244)
2024 (22095)
2023 (41284)
2022 (52113)
2021 (57042)
2020 (55569)
2019 (48735)
2018 (36630)
2017 (32103)
2016 (30369)
2015 (35475)
2014 (24629)
2013 (19206)
2012 (20727)
2011 (21532)
2010 (18623)
595,524 Results for "medivir ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Number of shares and votes in Medivir AB on 28 June 2024
Medivir AB announces that the number of shares and votes in Medivir has changed during June 2024 as a result of the issue of 1,700,000 shares of series C and the reclassification of 114 587 shares of series C to ordinary shares which was carried out as a part of the implementation of the incentive program resolved by the general meeting on 7 May 2024.
June 28, 2024
·
2 min read
Medivir to present at Redeye Growth Day
Medivir AB announces that the company will participate at Redeye Growth Day, today May 30, 2024.
May 30, 2024
·
1 min read
Number of shares and votes in Medivir AB on 31 January 2024
Medivir AB announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the rights issue resolved on by Medivir on 7 November 2023 and the directed issue to Hallberg Management AB resolved on by Medivir on 22 January 2024.
January 31, 2024
·
2 min read
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Medivir AB announced that Medivir’s licensee, Tango Therapeutics, has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.
May 23, 2024
·
2 min read
Drug Development
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
Medivir AB announced that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide + Lenvima® vs Lenvima alone in second line HCC.
June 19, 2024
·
4 min read
Business
Medivir 2023 Annual Report published
Medivir AB announces that the Annual Report for 2023 now is available at the company’s website.
April 4, 2024
·
2 min read
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
Medivir AB presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide + Lenvima® in advanced hepatocellular carcinoma at the ESMO GI Cancers Congress in Munich, Germany.
June 27, 2024
·
6 min read
Medivir to present at Investing in Oncology Forum on April 10
Medivir AB announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.
April 9, 2024
·
1 min read
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
Medivir AB announced that an abstract for the combination of fostroxacitabine bralpamide + Lenvima® in hepatocellular carcinoma has been accepted for presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress in June 26-29, 2024 in Munich.
April 29, 2024
·
3 min read
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET.
April 29, 2024
·
1 min read
1 of 59,553
Next
